We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+25.82%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$11.2M
Cap. Flow
+$12.8M
Cap. Flow %
7.01%
Top 10 Hldgs %
33.05%
Holding
110
New
26
Increased
27
Reduced
30
Closed
19

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$9.45M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.59M
3
MRUS
Merus
MRUS
+$5.65M
4
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.12M
5
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.14M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$7.21M
2
EPIX
ESSA Pharma
EPIX
+$5.8M
3
DCTH icon
Delcath Systems
DCTH
+$5.74M
4
STRO icon
Sutro Biopharma
STRO
+$4.02M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 85.57%
2 Financials 3.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
76
Rocket Pharmaceuticals
RCKT
$340M
$444K 0.24%
10,000
– –
MDNA
77
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$439K 0.24%
107,536
– –
PNT
78
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$420K 0.23%
40,000
+991
+3% +$13.4K
MRSN
79
DELISTED
Mersana Therapeutics
MRSN
$405K 0.22%
1,000
+569
+132% +$276K
ATNM icon
80
Actinium Pharmaceuticals
ATNM
$26.3M
$350K 0.19%
45,910
-44,090
-49% -$375K
ARDX icon
81
Ardelyx
ARDX
$1.22B
$298K 0.16%
45,000
-75,000
-63% -$515K
RXDX
82
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$274K 0.15%
+15,000
New +$310K
VIRX
83
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$264K 0.14%
+28,570
New +$298K
WVE icon
84
Wave Life Sciences
WVE
$1.09B
$224K 0.12%
+40,000
New +$384K
GMDA
85
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$189K 0.1%
23,393
-47,459
-67% -$436K
SLNO
86
DELISTED
Soleno Therapeutics
SLNO
$158K 0.09%
8,333
-13,187
-61% -$425K
BDTX icon
87
Black Diamond Therapeutics
BDTX
$96.8M
$146K 0.08%
+6,000
New +$162K
PVLA
88
Palvella Therapeutics
PVLA
$1.99B
$129K 0.07%
+625
New +$137K
PHGE icon
89
BiomX
PHGE
$1.99M
$98K 0.05%
72
– –
CHAQ.WS
90
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
$93K 0.05%
98,756
– –
CALA
91
DELISTED
Calithera Biosciences, Inc
CALA
$73K 0.04%
1,500
+750
+100% +$43.6K
ARQT icon
92
Arcutis Biotherapeutics
ARQT
$3.36B
– –
-8,505
Closed -$239K
BCRX icon
93
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-110,000
Closed -$820K
CGEN icon
94
CALL
Compugen
CGEN
$222M
– –
-20,000
Closed -$242K
CLDX icon
95
Celldex Therapeutics
CLDX
$2.99B
– –
-80,282
Closed -$1.41M
EXAS
96
DELISTED
Exact Sciences
EXAS
– –
-5,000
Closed -$662K
IOVA icon
97
Iovance Biotherapeutics
IOVA
$1.82B
– –
-10,000
Closed -$464K
NKTX icon
98
Nkarta
NKTX
$150M
– –
-15,000
Closed -$922K
NXTC icon
99
NextCure
NXTC
$16.8M
– –
-10,833
Closed -$1.42M
PTGX icon
100
Protagonist Therapeutics
PTGX
$8.79B
– –
-20,910
Closed -$422K
1 2 3
4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Silverarc Capital Management held 110 positions worth $183M, up 6.5% from $172M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management deployed $12.8M of net new capital in Q1 2021, opening 26 new positions and adding to 27 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Vericel Corp, an estimated $7.21M trimmed.

  • Silverarc Capital Management's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 500,000 shares worth $1.71M.
  • Silverarc Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021, an estimated $2.72M increase.
  • Silverarc Capital Management's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $7.21M.
  • Silverarc Capital Management fully exited Sutro Biopharma in Q1 2021, selling an estimated $4.02M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $183M portfolio in Q1 2021.
  • Silverarc Capital Management opened 26 new positions and closed 19 in Q1 2021.
  • Silverarc Capital Management's portfolio value rose 6.5% quarter-over-quarter to $183M.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.